Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2476${count})

  • MJFF Research Grant, 2011
    Drug Rescue of PINK1 Kinase Activity - A New Therapeutic Modality For Treating PD

    Objective/Rationale: 
    Many genetic disorders are caused by the loss of a functional protein which protects cells from disease. These disorders are difficult to treat with drugs because most drugs block...

  • Target Validation, 2011
    Gene delivery of miRNAs to reduce alpha synuclein: a new therapy for PD

    Objective/Rationale: 
    Alpha synuclein is a protein that in excessive amounts is implicated in Parkinson’s disease (PD). Alpha synuclein is also known to be the major constituent of a signature...

  • Target Validation, 2011
    Overexpression of CSPalpha Using Viral Vectors in the Striatum of a-Syn 1-120 Transgenic Pre-clinicalModel

    Objective/Rationale:
    Research data have recently indicated that pathology in Parkinson’s disease (PD) starts at the synapse, the part of the neurons where release of dopamine occurs, dysfunction of...

  • Rapid Response Innovation Awards, 2011
    Role of Striatal-Enriched Protein Tyrosine Phosphatase 61 (STEP61) in Parkinson's Disease

    Objective/Rationale:
    The Park2 gene product parkin is implicated in both genetic and sporadic forms of Parkinson’s disease (PD). Defective parkin function leads to the accumulation of toxic proteins...

  • Target Validation, 2011
    Pre-clinical Models Specifying Nicotinic Receptor Targets in Parkinson's Disease Neuroprotection

    Objective/Rationale:
    The scientific community has known since 1959 that tobacco use has apparent protective effects against Parkinson’s disease (PD), and some animal models suggest that this...

  • Dyskinesia, 2011
    The Nur77/RXR Transcriptional Complex as a New Target in L-Dopa-induced Dyskinesia Treatment

    Objective/Rationale:
    Transcription factors are nuclear proteins that regulate gene expression. They are likely to play an important role in long-term molecular maladaptive processes such as those...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.